Key recent events from the European and US biosimilars market; insulin, PegF and trastuzumab

Insulin generics hit the US, but what about biosimilars?

Drug prices around the world, in particular in the US, continue to capture the headlines. And significant price differences between developed markets, like the US and UK, are inflaming an already delicate situation.

In specific classes of drugs like insulin, prices in the US doubled between 2012 and 2016, according to an analysis shared with Reuters, even in older segments of the market. And this is a class of medication that is absolutely essential to patient health. Going without is not an option.

This hasn’t gone unnoticed by certain members of the US Senate. In February 2019…

To read more of this article, please head on over to IQPC’s Biosimilars Blog to gain access.

Will teenage years see the biosimilars market reach new heights, or will its growing pains continue?

2019 sees the biosimilars market reach teenage status. How will this influence future market growth?

Can positive experiences learned during the early years of growth be leveraged for continued future market success? Or have we seen the best that the market has to offer?

In April 2006, Sandoz received European Medicines Agency (EMA) approval for Omnitrope, its biosimilar version of the somatropin…

To continue reading this article, please visit IQPC’s biosimilars blog page. While you’re there you could also download the agenda for their forthcoming Biosimilars Commercialisation Summit (Amsterdam; May 14-16, 2019).

Let’s see where this takes us…

This week has been weird. Good weird, but weird all the same. More to follow on that soon. One of the side-effects of my weird week was a realisation that I’d not updated my blog for over two years. Time flies when you’re…well, time flies.

Lots of questions followed my realisation. Have I missed the boat when it come to blogging about biosimilars? What else is there left to talk about? And is there room left for a blogger like me? I mean, some of the guys who comment on the biosimilars market are pretty damn good.

Suffice to say I can’t answer these questions. I’m looking forward to finding out. Let’s see where this takes us, as I’m back…